Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review

GlobalData
48 Pages - GLDATA60713
$125.00

Halozyme Therapeutics Inc (HALO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Halozyme Therapeutics Inc (Halozyme) is a biotechnology company focusing on the development and commercialization of novel recombinant human enzymes to provide innovative products for cancer, dermatology, diabetes and drug delivery markets. The company’s products portfolio depends on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes affecting the extracellular matrix. Its Enhanze technology is a novel drug delivery platform proposed to enhance the absorption and dispersion of biologics. The company’s marketed product, Hylenex is an agent for drug and fluid infusion. Its pipeline products include analog insulin PH20, for the treatment of diabetes; PEGPH20, for the treatment of pancreatic cancer; and HTI-501, for the treatment of scarring, among others. The company has partnerships with Pfizer, Roche, Baxter and Intrexon for the development and commercialization of drugs. Halozyme is headquartered in San Diego, California, the US.

Halozyme Therapeutics Inc Key Recent Developments

Feb 28,2017: Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results
Nov 07,2016: Halozyme Reports Third Quarter 2016 Financial Results
Sep 01,2016: Halozyme Names Mark J. Gergen As Chief Operating Officer
Aug 09,2016: Halozyme Reports Second Quarter 2016 Financial Results
Jun 08,2016: Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

'

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Halozyme Therapeutics Inc - Key Facts 5
Halozyme Therapeutics Inc - Key Employees 6
Halozyme Therapeutics Inc - Key Employee Biographies 7
Halozyme Therapeutics Inc - Major Products and Services 9
Halozyme Therapeutics Inc - Pharmaceutical Pipeline Products Data 10
Halozyme Therapeutics Inc, Pipeline Products by Therapy Area 10
Halozyme Therapeutics Inc, Pipeline Products by Development Phase 10
Halozyme Therapeutics Inc - History 12
Halozyme Therapeutics Inc - Company Statement 15
Halozyme Therapeutics Inc - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Section 2 – Company Analysis 18
Halozyme Therapeutics Inc - Business Description 18
Halozyme Therapeutics Inc - Corporate Strategy 19
Halozyme Therapeutics Inc - SWOT Analysis 20
SWOT Analysis - Overview 20
Halozyme Therapeutics Inc - Strengths 20
Halozyme Therapeutics Inc - Weaknesses 21
Halozyme Therapeutics Inc - Opportunities 22
Halozyme Therapeutics Inc - Threats 23
Halozyme Therapeutics Inc - Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33
Halozyme Therapeutics Inc, Recent Deals Summary 34
Section 5 – Company’s Recent Developments 35
Feb 28, 2017: Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results 35
Nov 07, 2016: Halozyme Reports Third Quarter 2016 Financial Results 37
Sep 01, 2016: Halozyme Names Mark J. Gergen As Chief Operating Officer 38
Aug 09, 2016: Halozyme Reports Second Quarter 2016 Financial Results 39
May 09, 2016: Halozyme Reports First Quarter 2016 Financial Results 41
Mar 07, 2016: Halozyme Appoints Jim Daly To Board Of Directors 42
Feb 29, 2016: Halozyme Reports Fourth Quarter And Full Year 2015 Financial Results 43
Section 6 – Appendix 44
Methodology 44
Ratio Definitions 44
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Halozyme Therapeutics Inc, Key Facts 5
Halozyme Therapeutics Inc, Key Employees 6
Halozyme Therapeutics Inc, Key Employee Biographies 7
Halozyme Therapeutics Inc, Major Products and Services 9
Halozyme Therapeutics Inc, Number of Pipeline Products by Development Stage 11
Halozyme Therapeutics Inc, History 12
Halozyme Therapeutics Inc, Subsidiaries 17
Halozyme Therapeutics Inc, Key Competitors 24
Halozyme Therapeutics Inc, Ratios based on current share price 25
Halozyme Therapeutics Inc 26
Halozyme Therapeutics Inc (Cont...1) 27
Halozyme Therapeutics Inc, Interim Ratios 29
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33
Halozyme Therapeutics Inc, Recent Deals Summary 34
Currency Codes 44
Capital Market Ratios 44
Equity Ratios 45
Profitability Ratios 45
Cost Ratios 46
Liquidity Ratios 46
Leverage Ratios 47
Efficiency Ratios 47

List of Figures
Halozyme Therapeutics Inc, Pipeline Products by Therapy Area 10
Halozyme Therapeutics Inc, Pipeline Products by Development Phase 10
Halozyme Therapeutics Inc, Performance Chart (2012 - 2016) 28
Halozyme Therapeutics Inc, Ratio Charts 30
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 33

$125.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838